Unidade de Investigación en Cardioloxía Celular e Molecular
C.C.M.
![Foto de Unidade de Investigación en Cardioloxía Celular e Molecular](/img/grupo.png)
![Foto de University of Turin](/img/noimage_org.png)
University of Turin
Turín, ItaliaPublicacións en colaboración con investigadores/as de University of Turin (8)
2020
-
P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects
European heart journal. Cardiovascular pharmacotherapy, Vol. 6, Núm. 1, pp. 31-42
-
The impact of optimal medical therapy on patients with recurrent acute myocardial infarction: Subanalysis from the BleeMACS study
International Journal of Cardiology, Vol. 318, pp. 1-6
2018
-
Association of Beta-Blockers with Survival on Patients Presenting with ACS Treated with PCI: A Propensity Score Analysis from the BleeMACS Registry
American Journal of Cardiovascular Drugs, Vol. 18, Núm. 4, pp. 299-309
2017
-
Complete or incomplete coronary revascularisation in patients with myocardial infarction and multivessel disease: A propensity score analysis from the "real-life" BleeMACS (Bleeding complications in a Multicenter registry of patients discharged with diagnosis of Acute Coronary Syndrome) registry
EuroIntervention, Vol. 13, Núm. 4, pp. 407-414
2016
-
BleeMACS: Rationale and design of the study
Journal of Cardiovascular Medicine, Vol. 17, Núm. 10, pp. 744-749
-
Impact of blood transfusion on in-hospital myocardial infarctions according to patterns of acute coronary syndrome: Insights from the BleeMACS registry
International Journal of Cardiology, Vol. 221, pp. 364-370
-
Safety and effectiveness of the new P2Y12r inhibitor agents vs clopidogrel in ACS patients according to the geographic area: East Asia vs Europe
International Journal of Cardiology, Vol. 220, pp. 488-495
2010
-
Des-acyl ghrelin has specific binding sites and different metabolic effects from ghrelin in cardiomyocytes
Endocrinology, Vol. 151, Núm. 7, pp. 3286-3298